Central Precocious Puberty
Gonadotropin-releasing hormone (GnRH) agonist Triptodur treats central precocious puberty via intramuscular injection.
Data from a phase 3 clinical trial found that triptorelin achieved positive results in patients age 2 and older with central precocious puberty.
Ovarian cyst and McCune-Albright syndrome were most responsible for the increased risk of non-congenital adrenal hyperplasia gonadotropin-independent precocious puberty.
Long-term treatment with the histrelin implant safely and effectively sustained gonadotropin suppression and improved predicted adult height in central precocious puberty.
Endocrinology Advisor Articles
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- AAP Shares List of 5 Unnecessary Pediatric Tests and Procedures
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients
- Optimal Timing of Gastric Bypass and Cholecystectomy When Both Procedures Clinically Indicated
- Does Asthma Contribute to Infertility?
- Short-Term Probiotics Increase Weight Loss in Overweight, Obesity